Business Context and Reporting Period
This Form 8-K was filed by Wilson Greatbatch Technologies, Inc. on February 16, 2005. The report details a strategic initiative to consolidate manufacturing and research operations to reduce costs and improve efficiency. The company operates in the medical technology sector, specifically focusing on capacitor and implantable medical battery manufacturing.
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial data disclosed relates to estimated future costs associated with the operational restructuring plan.
- Total Estimated Consolidation Cost: $3.5 million to $4.0 million.
- Expense Recognition Period: Expected to be incurred over the next four fiscal quarters.
- Cost Composition: Primarily cash expenditures.
Material Changes and Operational Restructuring
The company approved a plan to consolidate operations as follows:
- Manufacturing Consolidation: Capacitor manufacturing (Cheektowaga, NY) and implantable medical battery manufacturing (Clarence, NY) will move to a new advanced power source facility in Alden, NY.
- R&D Consolidation: Capacitor research, development, and engineering (Cheektowaga, NY) will move to the existing battery R&D facility in Clarence, NY.
Estimated Cost Breakdown:
- Production inefficiencies and revalidation: $1.5 million to $1.7 million.
- Training: $0.6 million to $0.7 million.
- Moving and facility closures: $0.9 million to $1.0 million.
- Infrastructure: $0.5 million to $0.6 million.
Guidance, Risks, and Forward-Looking Statements
Management states that actual results could differ materially from the estimates provided. The filing includes a standard disclaimer regarding forward-looking statements and lists several risks that could impact the company's ability to execute this plan or achieve expected results:
- Dependence on a limited number of customers and customer ordering patterns.
- Pricing pressure and product obsolescence.
- Reliance on third-party suppliers for raw materials.
- Regulatory changes in the healthcare industry.
- Challenges in integrating acquisitions and maintaining quality standards.
Investor Verification Checklist
- Verify the timeline for the completion of the new Alden, NY facility construction.
- Monitor quarterly earnings reports for the actual recognition of the $3.5 to $4.0 million restructuring charges.
- Assess the impact of facility closures on current production capacity and customer delivery schedules.
- Review the company's cash position to ensure sufficient liquidity to fund the primarily cash-based expenditures.
- Check for any updates on the integration of R&D teams and potential delays in product development cycles.